Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome

Jason Lockrow, Heather Boger, Heather Bimonte-Nelson, Ann Charlotte Granholm

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Memantine is a partial NMDA receptor antagonist that has been shown to improve learning and memory in several animal models, and is approved for the treatment of Alzheimer's disease (AD). Chronic treatments using memantine in animal models of Alzheimer's disease show disease-modifying effects and suggest a potential neuroprotective function. The present study assessed the effects of both short- and long-term memantine treatment in a mouse model of Down syndrome (DS), the Ts65Dn mouse. The Ts65Dn mouse contains a partial trisomy of murine chromosome 16, and exhibits hippocampal-dependent memory deficits, as well as progressive degeneration of basal forebrain cholinergic neurons (BCFNs). Ts65Dn mice were treated with memantine for a period of 6 months, beginning at 4 months of age. At the end of treatment the mice underwent memory testing using novel object recognition and water radial arm maze tasks, and then histologically analyzed for markers of neurodegeneration. Memantine treatment improved spatial and recognition memory performance in the Ts65Dn mice, though not to the level of normosomic littermate controls. Despite these memory improvements, histological analysis found no morphological signs of neuroprotection of basal forebrain cholinergic or locus coeruleus neurons in memantine-treated Ts65Dn mice. However, memantine treatment of Ts65Dn mice gave rise to elevated brain-derived neurotrophic factor expression in the hippocampus and frontal cortex, suggesting a mechanism of behavioral modification. Thus, our findings provide further evidence for memory facilitation of memantine, but suggest pharmacological rather than neuroprotective effects of memantine both after acute and chronic treatment in this mouse model.

Original languageEnglish (US)
Pages (from-to)610-622
Number of pages13
JournalBehavioural Brain Research
Volume221
Issue number2
DOIs
StatePublished - Aug 10 2011

Fingerprint

Memantine
Down Syndrome
Alzheimer Disease
Animal Models
Neuropathology
Cholinergic Neurons
Locus Coeruleus
Trisomy
Brain-Derived Neurotrophic Factor
Memory Disorders
Frontal Lobe
Neuroprotective Agents
N-Methyl-D-Aspartate Receptors
Cholinergic Agents
Hippocampus
Learning
Pharmacology
Neurons

Keywords

  • Alzheimer's disease
  • BDNF
  • Brain derived growth factor
  • Cholinergic neuron
  • Hippocampus
  • Inflammation
  • Novel object recognition
  • Radial arm maze

ASJC Scopus subject areas

  • Behavioral Neuroscience

Cite this

Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. / Lockrow, Jason; Boger, Heather; Bimonte-Nelson, Heather; Granholm, Ann Charlotte.

In: Behavioural Brain Research, Vol. 221, No. 2, 10.08.2011, p. 610-622.

Research output: Contribution to journalArticle

Lockrow, Jason ; Boger, Heather ; Bimonte-Nelson, Heather ; Granholm, Ann Charlotte. / Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. In: Behavioural Brain Research. 2011 ; Vol. 221, No. 2. pp. 610-622.
@article{f46eb78555bd4e7c89009899ec22b8e6,
title = "Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome",
abstract = "Memantine is a partial NMDA receptor antagonist that has been shown to improve learning and memory in several animal models, and is approved for the treatment of Alzheimer's disease (AD). Chronic treatments using memantine in animal models of Alzheimer's disease show disease-modifying effects and suggest a potential neuroprotective function. The present study assessed the effects of both short- and long-term memantine treatment in a mouse model of Down syndrome (DS), the Ts65Dn mouse. The Ts65Dn mouse contains a partial trisomy of murine chromosome 16, and exhibits hippocampal-dependent memory deficits, as well as progressive degeneration of basal forebrain cholinergic neurons (BCFNs). Ts65Dn mice were treated with memantine for a period of 6 months, beginning at 4 months of age. At the end of treatment the mice underwent memory testing using novel object recognition and water radial arm maze tasks, and then histologically analyzed for markers of neurodegeneration. Memantine treatment improved spatial and recognition memory performance in the Ts65Dn mice, though not to the level of normosomic littermate controls. Despite these memory improvements, histological analysis found no morphological signs of neuroprotection of basal forebrain cholinergic or locus coeruleus neurons in memantine-treated Ts65Dn mice. However, memantine treatment of Ts65Dn mice gave rise to elevated brain-derived neurotrophic factor expression in the hippocampus and frontal cortex, suggesting a mechanism of behavioral modification. Thus, our findings provide further evidence for memory facilitation of memantine, but suggest pharmacological rather than neuroprotective effects of memantine both after acute and chronic treatment in this mouse model.",
keywords = "Alzheimer's disease, BDNF, Brain derived growth factor, Cholinergic neuron, Hippocampus, Inflammation, Novel object recognition, Radial arm maze",
author = "Jason Lockrow and Heather Boger and Heather Bimonte-Nelson and Granholm, {Ann Charlotte}",
year = "2011",
month = "8",
day = "10",
doi = "10.1016/j.bbr.2010.03.036",
language = "English (US)",
volume = "221",
pages = "610--622",
journal = "Behavioural Brain Research",
issn = "0166-4328",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome

AU - Lockrow, Jason

AU - Boger, Heather

AU - Bimonte-Nelson, Heather

AU - Granholm, Ann Charlotte

PY - 2011/8/10

Y1 - 2011/8/10

N2 - Memantine is a partial NMDA receptor antagonist that has been shown to improve learning and memory in several animal models, and is approved for the treatment of Alzheimer's disease (AD). Chronic treatments using memantine in animal models of Alzheimer's disease show disease-modifying effects and suggest a potential neuroprotective function. The present study assessed the effects of both short- and long-term memantine treatment in a mouse model of Down syndrome (DS), the Ts65Dn mouse. The Ts65Dn mouse contains a partial trisomy of murine chromosome 16, and exhibits hippocampal-dependent memory deficits, as well as progressive degeneration of basal forebrain cholinergic neurons (BCFNs). Ts65Dn mice were treated with memantine for a period of 6 months, beginning at 4 months of age. At the end of treatment the mice underwent memory testing using novel object recognition and water radial arm maze tasks, and then histologically analyzed for markers of neurodegeneration. Memantine treatment improved spatial and recognition memory performance in the Ts65Dn mice, though not to the level of normosomic littermate controls. Despite these memory improvements, histological analysis found no morphological signs of neuroprotection of basal forebrain cholinergic or locus coeruleus neurons in memantine-treated Ts65Dn mice. However, memantine treatment of Ts65Dn mice gave rise to elevated brain-derived neurotrophic factor expression in the hippocampus and frontal cortex, suggesting a mechanism of behavioral modification. Thus, our findings provide further evidence for memory facilitation of memantine, but suggest pharmacological rather than neuroprotective effects of memantine both after acute and chronic treatment in this mouse model.

AB - Memantine is a partial NMDA receptor antagonist that has been shown to improve learning and memory in several animal models, and is approved for the treatment of Alzheimer's disease (AD). Chronic treatments using memantine in animal models of Alzheimer's disease show disease-modifying effects and suggest a potential neuroprotective function. The present study assessed the effects of both short- and long-term memantine treatment in a mouse model of Down syndrome (DS), the Ts65Dn mouse. The Ts65Dn mouse contains a partial trisomy of murine chromosome 16, and exhibits hippocampal-dependent memory deficits, as well as progressive degeneration of basal forebrain cholinergic neurons (BCFNs). Ts65Dn mice were treated with memantine for a period of 6 months, beginning at 4 months of age. At the end of treatment the mice underwent memory testing using novel object recognition and water radial arm maze tasks, and then histologically analyzed for markers of neurodegeneration. Memantine treatment improved spatial and recognition memory performance in the Ts65Dn mice, though not to the level of normosomic littermate controls. Despite these memory improvements, histological analysis found no morphological signs of neuroprotection of basal forebrain cholinergic or locus coeruleus neurons in memantine-treated Ts65Dn mice. However, memantine treatment of Ts65Dn mice gave rise to elevated brain-derived neurotrophic factor expression in the hippocampus and frontal cortex, suggesting a mechanism of behavioral modification. Thus, our findings provide further evidence for memory facilitation of memantine, but suggest pharmacological rather than neuroprotective effects of memantine both after acute and chronic treatment in this mouse model.

KW - Alzheimer's disease

KW - BDNF

KW - Brain derived growth factor

KW - Cholinergic neuron

KW - Hippocampus

KW - Inflammation

KW - Novel object recognition

KW - Radial arm maze

UR - http://www.scopus.com/inward/record.url?scp=79955723158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955723158&partnerID=8YFLogxK

U2 - 10.1016/j.bbr.2010.03.036

DO - 10.1016/j.bbr.2010.03.036

M3 - Article

C2 - 20363261

AN - SCOPUS:79955723158

VL - 221

SP - 610

EP - 622

JO - Behavioural Brain Research

JF - Behavioural Brain Research

SN - 0166-4328

IS - 2

ER -